闻玉梅，复旦大学，上海——HBV相关实验室及人物介绍系列
本帖最后由 bigben446 于 2016-5-10 00:52 编辑闻玉梅院士，复旦大学上海医学院，上海
乙克疫苗，建立了上海医学院医学分子病毒实验室http://mvlab-fudan.cn/
Yi, G. and Y. Wen, et al. (2016). "Hepatitis C Virus NS4B Can Suppress STING Accumulation To Evade Innate Immune Responses." J Virol 90(1): 254-65.
Wang, W. and J. Li, et al. (2016). "A Pilot Study of MicroRNAs Expression Profile in Serum and HBsAg Particles: Predictors of Therapeutic Vaccine Efficacy in Chronic Hepatitis B Patients." Medicine (Baltimore) 95(2): e2511.
Wang, W. and L. Sun, et al. (2016). "A human monoclonal antibody against small envelope protein of hepatitis B virus with potent neutralization effect." MAbs 8(3): 468-77.
Zhao, Q. and Y. Wen, et al. (2016). "Next Generation Sequencing-Based Investigation of Potential Patient-to-Patient Hepatitis C Virus Transmission during Hemodialytic Treatment." PLoS One 11(1): e0147566.
Wen, Y. and X. Lin, et al. (2015). "The juxtamembrane sequence of the Hepatitis C virus polymerase can affect RNA synthesis and inhibition by allosteric polymerase inhibitors." Virus Genes 51(1): 1-11.
Wen, Y. and Y. X. Zheng, et al. (2015). "A comprehensive long-term prognosis of chronic hepatitis C patients with antiviral therapy: a meta-analysis of studies from 2008 to 2014." Hepat Mon 15(5): e27181.
Yamane, D. and D. R. McGivern, et al. (2014). "Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation." Nat Med 20(8): 927-35.
Wen, Y. and X. Wang, et al. (2014). "Vaccine therapies for chronic hepatitis B: can we go further?" Front Med 8(1): 17-23.
Wen, Y. and K. C. Cheng (2014). "The hepatitis C virus core protein can modulate RNA-dependent RNA synthesis by the 2a polymerase." Virus Res 189: 165-76.
Hong, R. and W. Bai, et al. (2013). "Novel recombinant hepatitis B virus vectors efficiently deliver protein and RNA encoding genes into primary hepatocytes." J Virol 87(12): 6615-24.
Jiao, B. and Y. Wen, et al. (2013). "." Nan Fang Yi Ke Da Xue Xue Bao 33(4): 486-90.
Xu, D. Z. and X. Y. Wang, et al. (2013). "Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings." J Hepatol 59(3): 450-6.
Tong, S. and J. Li, et al. (2013). "Hepatitis B virus genetic variants: biological properties and clinical implications." Emerg Microbes Infect 2(3): e10.
Yan, Y. and N. Liu, et al. (2013). "Autophagy enhances antitumor immune responses induced by irradiated hepatocellular carcinoma cells engineered to express hepatitis B virus X protein." Oncol Rep 30(2): 993-9.
Cheng, X. and S. Wang, et al. (2012). "Rabbit as a novel animal model for hepatitis E virus infection and vaccine evaluation." PLoS One 7(12): e51616.
Wen, Y. F. and X. F. Cheng, et al. (2012). "." Zhonghua Liu Xing Bing Xue Za Zhi 33(3): 347-8.
He, H. and P. Fan, et al. (2012). "Local delivery of recombinant adenovirus expressing hepatitis B virus X protein and interleukin-12 results in antitumor effects via inhibition of hepatoma cell growth and intervention of tumor microenvironment." Int J Mol Med 30(3): 599-605.
Xu, J. and H. Liu, et al. (2012). "Hepatitis B virus X protein confers resistance of hepatoma cells to anoikis by up-regulating and activating p21-activated kinase 1." Gastroenterology 143(1): 199-212.e4.
Cheng, X. F. and Y. F. Wen, et al. (2012). "Serological and molecular study of hepatitis E virus among illegal blood donors." World J Gastroenterol 18(9): 986-90.
Xia, Q. F. and Y. A. Wen, et al. (2011). "Use of duplex mutation primers for real-time PCR quantification of hepatitis C virus RNA in serum." Hepat Mon 11(7): 519-24.
Yao, X. and X. Y. Wang, et al. (2011). "Transcriptional analysis of immune-related genes in dendritic cells from hepatitis B surface antigen (HBsAg)-positive transgenic mice and regulation of Fc gamma receptor IIB by HBsAg-anti-HBs complex." J Med Virol 83(1): 78-87.
Liu, H. and J. Xu, et al. (2011). "Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway." Cancer Res 71(24): 7547-57.
Zhao, C. and W. Zhang, et al. (2010). "Proteomic analysis of cell lines expressing small hepatitis B surface antigen revealed decreased glucose-regulated protein 78 kDa expression in association with higher susceptibility to apoptosis." J Med Virol 82(1): 14-22.
Tian, X. and C. Zhao, et al. (2010). "Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin a secretion: possible link to pathogenesis of HBV infection." J Virol 84(7): 3373-81.
Xu, J. and X. Yun, et al. (2010). "Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage." Hepatology 52(1): 142-54.
Wang, X. Y. and X. X. Zhang, et al. (2010). "Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine." Vaccine 28(51): 8169-74.
Li, Y. and P. Cheng, et al. (2010). "T lymphocyte responses against hepatitis B virus-related hepatocellular carcinoma induced by adenovirus vaccine encoding HBx." Int J Mol Med 26(6): 869-76.
Wen, Y. and L. Y. Feng, et al. (2009). "Controlling hepatitis C with immunotherapy." Lancet Infect Dis 9(11): 652-3.
Hu, X. B. and Q. H. Yue, et al. (2009). "Hepatitis B virus genotypes and evolutionary profiles from blood donors from thenorthwest region of China." Virol J 6: 199.
Lu, H. M. and P. Cheng, et al. (2009). "." Sichuan Da Xue Xue Bao Yi Xue Ban 40(5): 803-6.
Bian, G. and Y. Cheng, et al. (2009). "Whole recombinant Hansenula polymorpha expressing hepatitis B virus surface antigen (yeast-HBsAg) induces potent HBsAg-specific Th1 and Th2 immune responses." Vaccine 28(1): 187-94.
Cheng, P. and Y. Li, et al. (2009). "Hepatitis B virus X protein (HBx) induces G2/M arrest and apoptosis through sustained activation of cyclin B1-CDK1 kinase." Oncol Rep 22(5): 1101-7.
Wang, X. Y. and X. Yao, et al. (2009). "." Zhonghua Gan Zang Bing Za Zhi 17(9): 718-20.
Tian, X. and J. Li, et al. (2009). "Role of hepatitis B surface antigen in the development of hepatocellular carcinoma: regulation of lymphoid enhancer-binding factor 1." J Exp Clin Cancer Res 28: 58.
Qin, J. and J. Zhai, et al. (2009). "Prospero-related homeobox protein (Prox1) inhibits hepatitis B virus replicationthrough repressing multiple cis regulatory elements." J Gen Virol 90(Pt 5): 1246-55.
Ma, Z. M. and X. Lin, et al. (2009). "A double-spliced defective hepatitis B virus genome derived from hepatocellular carcinoma tissue enhanced replication of full-length virus." J Med Virol 81(2): 230-7.
Wen, Y. M. and Y. X. Wang (2009). "Biological features of hepatitis B virus isolates from patients based on full-length genomic analysis." Rev Med Virol 19(1): 57-64.
Xu, D. Z. and K. Zhao, et al. (2008). "A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients." PLoS One 3(7): e2565.
Qu, D. and G. Lanier, et al. (2008). "Localization of CD8+ cells specific for hepatitis B virus surface protein in theliver of immunized mice." J Med Virol 80(2): 225-32.
Wen, Y. and V. S. Golubkov, et al. (2008). "Interaction of hepatitis B viral oncoprotein with cellular target HBXIP dysregulates centrosome dynamics and mitotic spindle formation." J Biol Chem 283(5): 2793-803.
Tian, X. and C. Zhao, et al. (2007). "Gene-expression profiles of a hepatitis B small surface antigen-secreting cell line reveal upregulation of lymphoid enhancer-binding factor 1." J Gen Virol 88(Pt 11): 2966-76.
Zhao, C. and C. Y. Fang, et al. (2007). "Proteomic analysis of hepatitis B surface antigen positive transgenic mouse liver and decrease of cyclophilin A." J Med Virol 79(10): 1478-84.
Wang, Y. X. and X. Xu, et al. (2007). "A putative new domain target for anti-hepatitis B virus: residues flanking hepatitis B virus reverse transcriptase residue 306 (rtP306)." J Med Virol 79(6): 676-82.
Wang, Y. X. and X. Xu, et al. (2007). "Mutational analysis revealed that conservation of hepatitis B virus reverse transcriptase residue 306 (rtP306) is crucial for encapsidation of pregenomic RNA." FEBS Lett 581(3): 558-64.
Yao, X. and B. Zheng, et al. (2007). "Therapeutic effect of hepatitis B surface antigen-antibody complex is associatedwith cytolytic and non-cytolytic immune responses in hepatitis B patients." Vaccine 25(10): 1771-9.
Fujii, R. and C. Zhu, et al. (2006). "HBXIP, cellular target of hepatitis B virus oncoprotein, is a regulator of centrosome dynamics and cytokinesis." Cancer Res 66(18): 9099-107.
Ren, J. and L. Wang, et al. (2006). "Gene expression profile of transgenic mouse kidney reveals pathogenesis of hepatitis B virus associated nephropathy." J Med Virol 78(5): 551-60.
Wen, Y. K. and M. L. Chen (2006). "Remission of hepatitis B virus-associated membranoproliferative glomerulonephritis in a cirrhotic patient after lamivudine therapy." Clin Nephrol 65(3): 211-5.
Liu, S. A. and D. Z. Xu, et al. (2006). "." Zhonghua Gan Zang Bing Za Zhi 14(2): 89-92.
Zhang, J. M. and X. Yao, et al. (2005). "High replicative full-length lamivudine-resistant hepatitis B virus isolated during acute exacerbations." J Med Virol 77(2): 203-8.
Lin, X. and Z. M. Ma, et al. (2005). "Substitution of proline 306 in the reverse transcriptase domain of hepatitis B virus regulates replication." J Gen Virol 86(Pt 1): 85-90.
Wang, X. Y. and Z. Xu, et al. (2004). "Immune responses of anti-HAV in children vaccinated with live attenuated and inactivated hepatitis A vaccines." Vaccine 22(15-16): 1941-5.
Zheng, B. J. and J. Zhou, et al. (2004). "Selective functional deficit in dendritic cell--T cell interaction is a crucial mechanism in chronic hepatitis B virus infection." J Viral Hepat 11(3): 217-24.
Wen, Y. M. (2004). "Structural and functional analysis of full-length hepatitis B virus genomes in patients: implications in pathogenesis." J Gastroenterol Hepatol 19(5): 485-9.
Wen, Y. M. (2003). "." Zhonghua Gan Zang Bing Za Zhi 11(9): 519-21.
Chua, P. K. and Y. M. Wen, et al. (2003). "Coexistence of two distinct secretion mutations (P5T and I97L) in hepatitis B virus core produces a wild-type pattern of secretion." J Virol 77(13): 7673-6.
Wen, Y. M. and X. Lin, et al. (2003). "Exploiting new potential targets for anti-hepatitis B virus drugs." Curr Drug Targets Infect Disord 3(3): 241-6.
Lin, X. and Z. M. Ma, et al. (2002). "Replication efficiency and sequence analysis of full-length hepatitis B virus isolates from hepatocellular carcinoma tissues." Int J Cancer 102(5): 487-91.
Hu, Y. and M. Tang, et al. (2002). "." Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 16(2): 114-8.
Lin, X. and Y. Wen, et al. (2002). "." Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 16(1): 11-5.
Lau, G. K. and Y. H. Leung, et al. (2002). "High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation." Blood 99(7): 2324-30.
Zheng, B. J. and M. H. Ng, et al. (2001). "Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice." Vaccine 19(30): 4219-25.
Lin, X. and G. S. Qian, et al. (2001). "Full-length genomic analysis of hepatitis B virus isolates in a patient progressing from hepatitis to hepatocellular carcinoma." J Med Virol 64(3): 299-304.
Wen, Y. M. (2001). "Laboratory diagnosis of viral hepatitis in China: the present and the future." Clin Chem Lab Med 39(12): 1183-9.
Wu, L. and Z. H. Yuan, et al. (2001). "Comparing the immunogenicity of hepatitis B virus S gene variants by DNA immunization." Viral Immunol 14(4): 359-67.
Lin, X. and Z. H. Yuan, et al. (2001). "A single amino acid in the reverse transcriptase domain of hepatitis B virus affects virus replication efficiency." J Virol 75(23): 11827-33.
Lin, X. and G. S. Qian, et al. (2001). "Full-length genomic analysis of hepatitis B virus isolates in a patient progressing from hepatitis to hepatocellular carcinoma." J Med Virol 64(4): 299-304.
Wen, Y. M. and D. Qu, et al. (1999). "Antigen-antibody complex as therapeutic vaccine for viral hepatitis B." Int Rev Immunol 18(3): 251-8.
Tu, H. and L. Gao, et al. (1999). "Hepatitis C virus RNA polymerase and NS5A complex with a SNARE-like protein." Virology 263(1): 30-41.
Wu, L. and J. W. He, et al. (1999). "A novel hepatitis B virus variant S 129 (Gln-->Leu): lack of correlation betweenantigenicity and immunogenicity." J Med Virol 59(4): 424-30.
Li, Y. and G. Li, et al. (1998). "Expression of structural proteins of hepatitis C virus (HCV) in mammalian cells." Sci China C Life Sci 41(1): 47-55.
McCluskie, M. J. and Y. M. Wen, et al. (1998). "Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes." Viral Immunol 11(4): 245-52.
He, J. W. and Q. Lu, et al. (1998). "Mutations in the 'a' determinant of hepatitis B surface antigen among Chinese infants receiving active postexposure hepatitis B immunization." Vaccine 16(2-3): 170-3.
Tu, H. and Y. Wen, et al. (1997). "." Zhonghua Yi Xue Za Zhi 77(8): 571-4.
Tu, H. and S. D. Xiong, et al. (1997). "Frequency of hepatitis B virus e-minus mutants varies among patients from different areas of China." J Med Virol 51(2): 85-9.
Ma, Z. M. and Y. Y. Kong, et al. (1996). "Recombinant vaccinia virus expressing Pre-S/S protein of duck hepatitis B virus and its preliminary use for treatment of persistent infection." Acta Virol 40(5-6): 311-4.
Tu, H. and P. Y. Li, et al. (1996). "Anti-HBe titre in patients infected with wild-type and e-minus variant of hepatitis B virus." Res Virol 147(1): 39-43.
Wen, Y. (1996). "Hepatitis B virus variants and their significance in pathogenesis, prevention and treatment." Chin Med J (Engl) 109(1): 39-41.
Wen, Y. M. and X. H. Wu, et al. (1995). "Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy." Lancet 345(8964): 1575-6.
Wen, Y. M. and S. Q. Guo, et al. (1994). "Enhanced immunogenicity in mice with hepatitis B vaccine complexed to human hepatitis B immunoglobulin." Chin Med J (Engl) 107(10): 741-4.
Wen, Y. M. and S. D. Xiong, et al. (1994). "Solid matrix-antibody-antigen complex can clear viraemia and antigenaemia in persistent duck hepatitis B virus infection." J Gen Virol 75 ( Pt 2): 335-9.
Wen, Y. M. (1993). "Hepatitis B virus precore and core gene mutations in chronic hepatitis B and hepatocellular carcinoma patients." J Intern Med 234(5): 441-5.
Li, J. S. and S. P. Tong, et al. (1993). "Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region." J Virol 67(9): 5402-10.
Wen, Y. M. and W. Zhang, et al. (1992). "Elimination of immune tolerance to hepatitis virus in an animal model." Chin Med J (Engl) 105(3): 199-203.
Wen, Y. M. (1992). "Study on the mechanisms of chronicity of hepatitis B infection." Chin Med J (Engl) 105(3): 183-8.
Wen, Y. M. and Y. Y. Xu, et al. (1990). "A synthetic peptide elicits antibody reactive with the native duck hepatitis B virus pre-S protein." J Gen Virol 71 ( Pt 10): 2467-9.
Wen, Y. M. and S. C. Duan, et al. (1990). "The affinity of anti-HBc antibodies in acute and chronic hepatitis B infection." Clin Exp Immunol 79(1): 83-6.
Wen, Y. M. (1989). "." Zhonghua Yi Xue Za Zhi 69(5): 260-3, 18.
Ye, M. J. and C. W. Zhang, et al. (1986). "." Hua Xi Yi Ke Da Xue Xue Bao 17(3): 212-5.
Wen, Y. M. (1986). "." Zhonghua Yi Xue Za Zhi 66(9): 521-4, 574.
Wen, Y. M. and H. J. Liu, et al. (1986). "Studies on intrahepatic hepatitis B virus DNA in 98 viral hepatitis B patients." Chin Med J (Engl) 99(11): 861-5.
Li, L. and M. H. Sheng, et al. (1986). "Transplacental transmission of hepatitis B virus." Lancet 2(8511): 872.
Xu, Z. Y. and D. P. Francis, et al. (1985). "Prevention of hepatitis B virus carriage of infants using HBV vaccine in Shanghai. Preliminary report of a randomized double-blind placebo-controlled trial." Chin Med J (Engl) 98(9): 623-6.
Wen, Y. M. and K. Mitamura, et al. (1983). "Nuclear antigen detected in hepatoma cell lines containing integrated hepatitis B virus DNA." Infect Immun 39(3): 1361-7.
页:
[1]